RxDoctor Payments Data

Marah Lee, DO

Internal Medicine · Oakland Park, FLNPI 1518923010

Payments from drug & device makers

$22,889in general payments, 2019–2025

Across 113 payments — averaging $202.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$13K
  • Gilead$9K
  • Theratechnologies Inc.$894
  • AstraZeneca$238
  • Insmed, Inc.$133
  • Johnson & Johnson$122
  • plus $173 from 8 others

What the payments were for

  • Consulting fees$11,09048%
  • Speaking & faculty fees$7,11031%
  • Travel & lodging$4322%
  • Food & beverage$4,25719%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,889 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$69,167
Medicare patients
111
Services billed
924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala213$863,376
GenvoyaElviteg/Cob/Emtri/Tenof Alafen105$419,750
TriumeqAbacavir/Dolutegravir/Lamivudi82$338,891
PrezcobixDarunavir/Cobicistat95$236,030
OdefseyEmtricitab/Rilpiviri/Tenof Ala50$189,095
DescovyEmtricitabine/Tenofov Alafenam71$173,176
TivicayDolutegravir Sodium62$151,176
CabenuvaCabotegravir/Rilpivirine22$142,774
TrogarzoIbalizumab-Uiyk11$132,632
RukobiaFostemsavir Tromethamine14$131,152
IsentressRaltegravir Potassium58$115,074
Isentress HdRaltegravir Potassium48$100,233
PrezistaDarunavir29$59,000
DovatoDolutegravir Sodium/Lamivudine19$56,680
PifeltroDoravirine27$47,224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$8,526$1,456,303389 claims
Viiv Healthcare CompanyTriumeq, Tivicay, Cabenuva, Rukobia, Dovato$12,802$820,672199 claims
MerckIsentress, Isentress Hd, Pifeltro$28$262,531133 claims
Johnson & JohnsonPrezcobix$122$236,03095 claims
Theratechnologies Inc.Trogarzo$894$132,63211 claims
Novo NordiskOzempic$45$42,49339 claims
Endo Pharmaceuticals Inc.Aveed$14$26,82314 claims
AstraZenecaFarxiga$238$19,84514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Oakland Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →